intraperitoneal microdialysis after server infektion i the peritoneal cavity

intraperitoneal microdialysis after server peritonitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-004398-22-DK

Enrollment

Registered

2013-04-10

Start date

2013-07-01

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

server peritonitis

Interventions

Trade Name: Metronidazol Product Name: Metronidazol Pharmaceutical Form: Infusion INN or Proposed INN: Metronidazole CAS Number: 443-48-1 Other descriptive name: METRONIDAZOLE Concentration unit: mg m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Suspecting peritonitis: perforated ulcer, perforated, diverticulitis of colon, perforated appendicitis, anastomitix leakage Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 25 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 25

Exclusion criteria

Exclusion criteria: Local abces eGFR<30

Design outcomes

Primary

Measure	Time frame
Main Objective: Comparing the intraperitoneal concentrations og antibiotics ( meronem, cefuroxim, tazocin, metronidazol og diflucan) with the patients clinic after operation for server peritonitis;Secondary Objective: Mesuring intraperitoneal concentration of metabolits ( glucose, glycerol, lactat, pyruvat, glutamat ) and cytocins.;Primary end point(s): -;Timepoint(s) of evaluation of this end point: 2018	—

Measure

Time frame

Main Objective: Comparing the intraperitoneal concentrations og antibiotics ( meronem, cefuroxim, tazocin, metronidazol og diflucan) with the patients clinic after operation for server peritonitis;Secondary Objective: Mesuring intraperitoneal concentration of metabolits ( glucose, glycerol, lactat, pyruvat, glutamat ) and cytocins.;Primary end point(s): -;Timepoint(s) of evaluation of this end point: 2018

—

Secondary

Measure	Time frame
Secondary end point(s): -;Timepoint(s) of evaluation of this end point: 2018	—

Countries

Denmark

Contacts

Public ContactAfd. A

afd. A

anne_r_axelsen@hotmail.com

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026